Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform
February 01, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
Signs a World-Wide Exclusive License with Stony Brook University for a Novel Platform that can Enhance Radionuclide TargetingReceives up to $2.4M NIH Grant to Develop Differentiated Antibody-based...
Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement
January 22, 2024 16:05 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement
January 18, 2024 07:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Therapeutics Announces Proposed Public Offering
January 17, 2024 16:05 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01
January 17, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced that it began patient recruitment for the second dosing cohorts (Cohort 2) in...
Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability
January 09, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
Lantheus will have the option to negotiate an exclusive license to Perspective Therapeutics’ Pb212-VMT-α-NETLantheus will have the option to co-fund and negotiate an exclusive license for certain...
Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment
January 05, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
Mayo Clinic’s PSMA Alpha-PET DoubLET platform allows for imaging and targeted therapy with alpha and/or beta-particle radiopharmaceutical therapy (RPT) using a novel 64/67Cu and 203/212Pb double...
Perspective Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that Thijs Spoor, the Company’s Chief Executive...
Perspective Therapeutics Divests Brachytherapy Business
December 12, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
SEATTLE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced it agreed to fully divest its brachytherapy...
Perspective Therapeutics Announces First Patient Dosed in a Phase 1 Study of [(212)Pb]VMT-α-NET to Treat Refractory or Relapsed Neuroendocrine Tumors
December 07, 2023 08:00 ET
|
Perspective Therapeutics, Inc.
First U.S. patient with refractory or relapsed SSTR2-positive neuroendocrine tumors treated with [212Pb]VMT-α-NETPreliminary data readout expected in second half of 2024 SEATTLE, Dec. 07, 2023 ...